Diethylpropion
Identification
- Name
- Diethylpropion
- Accession Number
- DB00937
- Description
A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290)
- Type
- Small Molecule
- Groups
- Approved, Illicit
- Structure
Structure for Diethylpropion (DB00937)
- Weight
- Average: 205.2961
Monoisotopic: 205.146664235 - Chemical Formula
- C13H19NO
- Synonyms
- (±)-diethylpropion
- 1-phenyl-2-diethylamino-1-propanone
- 2-(diethylamino)-1-phenyl-1-propanone
- 2-(diethylamino)propiophenone
- alpha-Benzoyltriethylamine
- alpha-Diethylaminopropiophenone
- Amfepramone
- Amfépramone
- Amfepramonum
- Anfepramona
- Diethylcathinone
- External IDs
- DEA No. 1610
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Used in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction.
- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Diethylpropion is a sympathomimetic stimulant drug marketed as an appetite suppressant. Chemically, it is the N,N-diethyl analog of cathinone. Its mechanism of action is similar to other appetite suppressants such as sibutramine, phentermine and dextroamphetamine.
- Mechanism of action
Diethylpropion is an amphetamine that stimulates neurons to release or maintain high levels of a particular group of neurotransmitters known as catecholamines; these include dopamine and norepinephrine. High levels of these catecholamines tend to suppress hunger signals and appetite. Diethylpropion (through catecholamine elevation) may also indirectly affect leptin levels in the brain. It is theorized that diethylpropion can raise levels of leptin which signal satiety. It is also theorized that increased levels of the catecholamines are partially responsible for halting another chemical messenger known as neuropeptide Y. This peptide initiates eating, decreases energy expenditure, and increases fat storage.
Target Actions Organism ASodium-dependent noradrenaline transporter inhibitorHumans ASodium-dependent dopamine transporter inhibitorHumans - Absorption
Diethylpropion is rapidly absorbed from the GI tract after oral administration.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Many of these metabolites are biologically active and may participate in the therapeutic action of diethylpropion.
- Route of elimination
Diethylpropion is rapidly absorbed from the GI tract after oral administration and is extensively metabolized through a complex pathway of biotransformation involving N-dealkylation and reduction. Diethylpropion and/or its active metabolites are believed to cross the blood-brain barrier and the placenta. Diethylpropion and its metabolites are excreted mainly by the kidney.
- Half-life
Using a phosphorescence assay that is specific for basic compounds containing benzoyl group, the plasma half-life of the aminoketone metabolites is estimated to be between 4 to 6 hours.
- Clearance
- Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
The reported oral LD50 for mice is 600 mg/kg, for rats is 250 mg/kg and for dogs is 225 mg/kg. Manifestation of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbaloparatide The risk or severity of adverse effects can be increased when Diethylpropion is combined with Abaloparatide. Acebutolol The therapeutic efficacy of Acebutolol can be decreased when used in combination with Diethylpropion. Aceclofenac The risk or severity of hypertension can be increased when Diethylpropion is combined with Aceclofenac. Acemetacin The risk or severity of hypertension can be increased when Diethylpropion is combined with Acemetacin. Acetazolamide Acetazolamide may decrease the excretion rate of Diethylpropion which could result in a higher serum level. Acetophenazine Acetophenazine may decrease the stimulatory activities of Diethylpropion. Acetylsalicylic acid The risk or severity of hypertension can be increased when Diethylpropion is combined with Acetylsalicylic acid. Aclidinium Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Acrivastine Diethylpropion may decrease the sedative and stimulatory activities of Acrivastine. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Diethylpropion. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Take with or without food. The absorption is unaffected by food.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Diethylpropion hydrochloride 19V2PL39NG 134-80-5 ICFXZZFWRWNZMA-UHFFFAOYSA-N - Product Images
- International/Other Brands
- Anorex / Dobesin / Frekentine / Linea / Moderatan / Neobes (Medix) / Nobesine / Prefamone / Regenon (Temmler) / Tylinal
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Diethylpropion HCl Controlled-Release Tablet 75 mg/1 Oral bryant ranch prepack 1960-11-17 Not applicable US 
Diethylpropion HCl Controlled-Release Tablet 75 mg/1 Oral Rebel Distributors 2008-01-01 Not applicable US 
Diethylpropion HCl Controlled-Release Tablet 75 mg/1 Oral A S Medication Solutions 1960-11-17 Not applicable US 
Diethylpropion HCl Controlled-Release Tablet 75 mg/1 Oral Actavis Pharma, Inc. 1960-11-17 2019-06-30 US 
Diethylpropion HCl Controlled-Release Tablet 75 mg/1 Oral Physicians Total Care, Inc. 2005-10-03 Not applicable US 
Diethylpropion HCl Controlled-Release Tablet 75 mg/1 Oral A-S Medication Solutions 1960-11-17 Not applicable US 
Diethylpropion HCl Controlled-Release Tablet 75 mg/1 Oral Preferred Pharmaceuticals, Inc. 2014-02-12 2019-08-26 US 
Diethylpropion HCl Controlled-Release Tablet 75 mg/1 Oral Nucare Pharmaceuticals, Inc. 1960-11-17 Not applicable US Diethylpropion HCl Immediate-Release Tablet 25 mg/1 Oral A-S Medication Solutions 1959-08-06 Not applicable US 
Diethylpropion HCl Immediate-Release Tablet 25 mg/1 Oral Pd Rx Pharmaceuticals, Inc. 1959-08-06 2018-08-03 US 
- Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Diethylpropion HCl Controlled-Release Tablet 75 mg/1 Oral Keltman Pharmaceuticals Inc. 2010-06-07 Not applicable US 
Diethylpropion HCl Controlled-Release Tablet 75 mg/1 Oral Blenheim Pharmacal, Inc. 2010-03-30 Not applicable US Diethylpropion HCl Immediate-Release Tablet 25 mg/1 Oral Keltman Pharmaceuticals Inc. 2010-06-07 Not applicable US 
Diethylpropion Hydrochloride Tablet 25 mg/1 Oral PD-Rx Pharmaceuticals, Inc. 2010-12-27 Not applicable US Diethylpropion Hydrochloride Tablet 25 mg/1 Oral bryant ranch prepack 2011-07-18 Not applicable US Diethylpropion Hydrochloride Tablet, extended release 75 mg/1 Oral H.J. Harkins Company, Inc. 2017-01-03 Not applicable US Diethylpropion Hydrochloride Tablet 25 mg/1 Oral Lannett Company, Inc. 2011-07-18 Not applicable US Diethylpropion Hydrochloride Tablet 25 mg/1 Oral Nucare Pharmaceuticals, Inc. 2011-07-18 2019-12-31 US Diethylpropion Hydrochloride Tablet 25 mg/1 Oral A-S Medication Solutions 2010-12-27 Not applicable US Diethylpropion Hydrochloride Tablet 25 mg/1 Oral KVK-TECH, INC 2010-12-27 Not applicable US
Categories
- ATC Codes
- A08AA03 — Amfepramone
- Drug Categories
- Agents producing tachycardia
- Agents that produce hypertension
- Alimentary Tract and Metabolism
- Amines
- Amphetamines
- Anti-Obesity Agents
- Antiobesity Preparations, Excl. Diet Products
- Appetite Depressants
- Appetite Suppression
- Central Nervous System Depressants
- Centrally Acting Antiobesity Products
- Ethylamines
- Increased Sympathetic Activity
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Stimulants
- Sympathomimetic Amine Anorectic
- Sympathomimetics
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Carbonyl compounds
- Direct Parent
- Alkyl-phenylketones
- Alternative Parents
- Phenylpropanes / Benzoyl derivatives / Aryl alkyl ketones / Alpha-amino ketones / Trialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alkyl-phenylketone / Alpha-aminoketone / Amine / Aromatic homomonocyclic compound / Aryl alkyl ketone / Benzenoid / Benzoyl / Hydrocarbon derivative / Monocyclic benzene moiety / Organic nitrogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- tertiary amine, aromatic ketone (CHEBI:4530)
Chemical Identifiers
- UNII
- Q94YYU22B8
- CAS number
- 90-84-6
- InChI Key
- XXEPPPIWZFICOJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3
- IUPAC Name
- 2-(diethylamino)-1-phenylpropan-1-one
- SMILES
- CCN(CC)C(C)C(=O)C1=CC=CC=C1
References
- Synthesis Reference
Schutte, J.; U.S. Patent 3,001,910; September 26, 1961; assigned to Firma Ternmler-Werke (W. Germany).
US3001910- General References
- Adan RA, Vanderschuren LJ, la Fleur SE: Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17. doi: 10.1016/j.tips.2008.01.008. Epub 2008 Mar 18. [PubMed:18353447]
- Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080]
- External Links
- Human Metabolome Database
- HMDB0015072
- KEGG Drug
- D07444
- KEGG Compound
- C06954
- PubChem Compound
- 7029
- PubChem Substance
- 46506622
- ChemSpider
- 6762
- 3389
- ChEBI
- 4530
- ChEMBL
- CHEMBL1194666
- Therapeutic Targets Database
- DAP001452
- PharmGKB
- PA164778098
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Amfepramone
- FDA label
- Download (114 KB)
- MSDS
- Download (103 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Terminated Treatment BMI >30 kg/m2 1
Pharmacoeconomics
- Manufacturers
- Sanofi aventis us llc
- Watson pharmaceuticals
- 3m pharmaceuticals inc
- Corepharma llc
- Sandoz inc
- Teva pharmaceuticals usa inc
- Tg united labs llc
- Ucb inc
- Watson laboratories inc
- Packagers
- Aidarex Pharmacuticals LLC
- Apotheca Inc.
- A-S Medication Solutions LLC
- Bryant Ranch Prepack
- Calvin Scott and Co. Inc.
- Carlisle Laboratories Inc.
- Corepharma LLC
- Darby Dental Supply Co. Inc.
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Keltman Pharmaceuticals Inc.
- Lake Erie Medical and Surgical Supply
- Landmark Chemical Co.
- Macnary Ltd.
- Merrell Pharmaceuticals Inc.
- Nucare Pharmaceuticals Inc.
- Patheon Inc.
- PD-Rx Pharmaceuticals Inc.
- Physicians Total Care Inc.
- Preferred Pharmaceuticals Inc.
- Prepak Systems Inc.
- Qualitest
- Quality Research Pharmaceutical Inc.
- Rebel Distributors Corp.
- Southwood Pharmaceuticals
- United Research Laboratories Inc.
- Watson Pharmaceuticals
- Dosage Forms
Form Route Strength Tablet, extended release Oral Tablet Oral 75 mg/1 Tablet Oral 25 mg/1 Capsule, extended release Oral Tablet Oral Tablet, extended release Oral 75 mg/1 - Prices
Unit description Cost Unit Diethylpropion HCl CR 75 mg 24 Hour tablet 1.0USD tablet Tenuate 25 mg tablet 0.67USD tablet Diethylpropion 25 mg tablet 0.52USD tablet Diethylpropion HCl 25 mg tablet 0.29USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 168 Schutte, J.; U.S. Patent 3,001,910; September 26, 1961; assigned to Firma Ternmler-Werke (W. Germany). logP 2.8 Not Available - Predicted Properties
Property Value Source Water Solubility 1.22 mg/mL ALOGPS logP 2.8 ALOGPS logP 2.7 ChemAxon logS -2.2 ALOGPS pKa (Strongest Acidic) 17.43 ChemAxon pKa (Strongest Basic) 7.44 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 20.31 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 63.88 m3·mol-1 ChemAxon Polarizability 24.12 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9354 Caco-2 permeable + 0.8532 P-glycoprotein substrate Non-substrate 0.5328 P-glycoprotein inhibitor I Non-inhibitor 0.8859 P-glycoprotein inhibitor II Non-inhibitor 0.9157 Renal organic cation transporter Non-inhibitor 0.6691 CYP450 2C9 substrate Non-substrate 0.8022 CYP450 2D6 substrate Non-substrate 0.6551 CYP450 3A4 substrate Non-substrate 0.6339 CYP450 1A2 substrate Inhibitor 0.7358 CYP450 2C9 inhibitor Non-inhibitor 0.952 CYP450 2D6 inhibitor Non-inhibitor 0.7815 CYP450 2C19 inhibitor Non-inhibitor 0.8088 CYP450 3A4 inhibitor Non-inhibitor 0.9438 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.6602 Ames test Non AMES toxic 0.9326 Carcinogenicity Carcinogens 0.5877 Biodegradation Not ready biodegradable 0.9236 Rat acute toxicity 2.6791 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8475 hERG inhibition (predictor II) Non-inhibitor 0.8179
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available GC-MS Spectrum - EI-B GC-MS splash10-0udi-9600000000-6ee5a640521355e9e385 Mass Spectrum (Electron Ionization) MS splash10-0udi-2900000000-43214c102b76f59ba4d1 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Accelerate your drug discovery research with our ADMET & drug target dataset
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Norepinephrine:sodium symporter activity
- Specific Function
- Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A2
- Uniprot ID
- P23975
- Uniprot Name
- Sodium-dependent noradrenaline transporter
- Molecular Weight
- 69331.42 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Monoamine transmembrane transporter activity
- Specific Function
- Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
- Gene Name
- SLC6A3
- Uniprot ID
- Q01959
- Uniprot Name
- Sodium-dependent dopamine transporter
- Molecular Weight
- 68494.255 Da
References
- Yu H, Rothman RB, Dersch CM, Partilla JS, Rice KC: Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters. Bioorg Med Chem. 2000 Dec;8(12):2689-92. [PubMed:11131159]
- Arias HR, Santamaria A, Ali SF: Pharmacological and neurotoxicological actions mediated by bupropion and diethylpropion. Int Rev Neurobiol. 2009;88:223-55. doi: 10.1016/S0074-7742(09)88009-4. [PubMed:19897080]
Drug created on June 13, 2005 13:24 / Updated on March 04, 2021 11:30